Eli Lilly (LLY) Releases Positive Results From Phase 3 VIVID-2 Open-Label Extension Study

Eli Lilly and Company (NYSE:LLY) is one of the Best Stocks to Buy and Hold For the Next 3 Years. On February 19, Eli Lilly and Company (NYSE:LLY) released positive results from the Phase 3 VIVID-2 open-label extension study. The study is testing Omvoh (mirikizumab-mrkz) to treat Crohn’s disease and ulcerative colitis.

​The study found durable remission in Crohn’s, as patients with moderate-to-severe Crohn’s stayed in remission after 3 years of treatment. Moreover, data from VIVID-1 (Crohn’s) and LUCENT-3 (ulcerative colitis) trials showed that the treatment requires minimal hospitalizations and surgeries. Management noted that Omvoh is the first IL-23p19 inhibitor with proven efficacy over 4 years in ulcerative colitis and 3 years in Crohn’s.

​Efficacy results at 152 weeks showed 92.4% clinical remission and 91.2% Corticosteroid-free clinical remission. Adrienne Brown, President of Immunology at Eli Lilly and Company (NYSE:LLY), noted that the trial proves that Omvoh helps patients achieve sustained control, potentially changing disease progression.

​Eli Lilly and Company (NYSE:LLY) is a pharmaceutical manufacturer. It develops treatments across therapeutic areas, including diabetes, oncology, immunology, and neuroscience.